NUFORMIX PLC

AGM Information • Sep 19, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3005B

Nuformix PLC

19 September 2018

Nuformix plc

Result of Annual General Meeting

The Annual General Meeting of Nuformix plc was held on 19th September 2018 at 1.00pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street, London, EC3V 0HR.

The Directors of the Company wish to announce that all the resolutions were passed by the required majority.  The results of the voting by poll on the resolutions put to the meeting are listed below. 

	Resolution	Ordinary/ Special	For*		Against		Total votes cast
			No. of votes	%	No. of votes	%
1	To receive the annual report and accounts for the year ended 31 March 2018	Ordinary	141,656,903	100	0	0	141,656,903
2	To approve the Directors' Remuneration Policy	Ordinary	134,767,823	95.14	6,889,080	4.86	141,656,903
3	To approve the Annual Report on Remuneration	Ordinary	134,767,823	95.14	6,889,080	4.86	141,656,903
4	To re-appoint David Tapolczay as a director	Ordinary	141,656,903	100	0	0	141,656,903
5	To re-appoint Daniel Gooding as a director	Ordinary	134,767,823	95.14	6,889,080	4.86	141,656,903
6	To re-appoint Joanne Holland as a director	Ordinary	141,656,903	100	0	0	141,656,903
7	To re-appoint John Lidgey as a director	Ordinary	141,656,903	100	0	0	141,656,903
8	To re-appoint Kirk Siderman-Wolter as a director	Ordinary	141,656,903	100	0	0	141,656,903
9	To re-Christopher Blackwell as a director	Ordinary	141,656,903	100	0	0	141,656,903
10	To re-appoint haysmacintyre as auditor	Ordinary	141,656,903	100	0	0	141,656,903
11	To authorise the Directors to determine the auditor's fees.	Ordinary	134,767,823	95.14	6,889,080	4.86	141,656,903
12	To authorise the Directors to allot shares.	Ordinary	134,767,823	95.14	6,889,080	4.86	141,656,903
13	To authorise the Directors to disapply pre-emption rights.	Special	134,767,823	95.14	6,889,080	4.86	141,656,903
14	To authorise the Company to purchase its own shares.	Special	134,767,823	95.14	6,889,080	4.86	141,656,903
15	To authorise calling of a general meeting on 14 clear days' notice.	Special	134,767,823	95.14	6,889,080	4.86	141,656,903

*The 'For' votes include those votes giving the Chairman discretion.                                                                     

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 460,750,000 ordinary shares of 0.1p each.

Copies of the resolutions passed as special resolutions at the AGM will shortly be available for inspection at the National Storage Mechanism, which is located at: http://www.morningstar.co.uk/uk/nsm.

19 September 2018

For further information please contact:

Nuformix plc Dr Dan Gooding, Chief Executive Officer	+44 (0)1223 423667
Gable Communications Ltd John Bick / Justine James	+44 (0)20 7193 7463

About Nuformix plc www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs.   Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.  Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGXKLFFVKFXBBF